There are two diseases in particular that may have serious consequences for driving and mobility due to their potentially severe impact on visual function: glaucoma and diabetic neuropathy. In this project we will develop predictive models of driving for these patients and will train them to use low-vision aids to improve driving mobility. We will determine how best to train patients with hemianopic field loss due to cerebral vascular accidents and identify predictors of long-term success in the use of low-vision aids.

Condition	Treatment or Intervention	Phase
Low Vision	Procedure: Low vision	Phase II

Further Study Details: 

Expected Total Enrollment:  30

There are two diseases in particular that may have serious consequences for driving and mobility due to their potentially severe impact on visual function: glaucoma and diabetic neuropathy. Both these diseases can potentially result in significant peripheral visual field loss, sometimes coupled with decreased visual acuity. We have previously demonstrated that each of these visual losses alone can have significant impact on driving and mobility performance. In this project we will develop predictive models of driving for these patients and apply our extensive expertise in training patients to use low-vision aids to improve driving mobility. A second question that will be addressed is how to best train scanning patients with hemianopic field loss due to cerebral vascular accidents. We propose to configure the prisms in a bioptic form similar to previously used for amorphic lenses in RP and for bioptic telescopes for patients in macular disease. The third problem that will be addressed is the identification of predictors of long-term success in the use of low-vision aids.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Eye impairment

Illinois
      VAMC (West Side), Chicago,  Illinois,  United States

Study chairs or principal investigators

John Fryer, Ph. D., Asst. Director,  Program Analysis and Review Section (PARS), Rehabilitation Research & Development Service   
Nancy Rocheleau, Program Analyst,  Program Analysis and Review Section (PARS), Rehabilitation Research & Development Service   

Study ID Numbers:  C1982
Record last reviewed:  January 2001
Last Updated:  October 13, 2004
Record first received:  March 14, 2001
ClinicalTrials.gov Identifier:  NCT00013377
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08